Lorcaserin for Treating Patients with Dravet Syndrome (Epilepsy)Research Question:
Does the drug, lorcaserin, affect the frequency of convulsive seizures in patients
with Dravet syndrome?
Basic Study Information
Purpose:Study Reference #: 5376
There is a Core Study and an Extension Phase. The Core Study will include a Pre-randomization
(Baseline) and a Randomization (Treatment) Phase. The Pre-randomization Phase will
include a Screening/Baseline Period (4 weeks), during which the subjects will be assessed
for eligibility. Once the Screening and Baseline procedures have been completed and
eligibility has been established, the subjects will be randomized to 1 of 2 treatment
groups in a ratio of 1:1 and will receive lorcaserin or placebo for 14 weeks. All
subjects who complete the Core Study will be eligible to enter the 16-week Open-label
Extension Phase. Eligibility: Aged 2 or older with a diagnosis of Dravet syndrome.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Noreen Connolly
Phone: (585) 275-0589
Additional Study Details
Number of Visits:
6 to 10
Learn More About These Conditions
More information about Epilepsy
Trial Not Found
The study you are looking for is not active at this time.
Return to Search